Docetaxel

Drug Profile

Docetaxel

Alternative Names: Docetaxol; NSC 628503; RP 56976; Taxotere; XPR 6976; XRP-6976

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Roche; Sanofi; University of Iowa; University of Texas M. D. Anderson Cancer Center; West German Study Group
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Registered Solid tumours
  • Phase I/II Sarcoma
  • Discontinued Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 22 Aug 2017 Genentech completes a phase I/II trial in Sarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Second-line therapy or greater, In adults, In the elderly) in USA (unspecified route) (NCT01106872)
  • 02 Jun 2017 Adverse events and efficacy data from the phase-II DECIDE trial in Head and neck cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 Jan 2017 Roche completes a phase III trial in Breast cancer (Combination therapy, Early-stage disease) in Netherlands, Belgium, Spain, Slovenia, Germany, United Kingdom, Italy, Portugal (IV) (NCT00433589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top